文献速递食管与纵隔外科

机器人胸腺切除术治疗胸腺上皮肿瘤的远期结局

Long-Term Outcomes of Robotic Thymectomy in Patients With Thymic Epithelial Tumors.
PubMed 文献 · Ann Thorac Surg · 2020-10-29

本研究纳入158例接受机器人胸腺切除术且随访超过1年的胸腺上皮肿瘤患者,中位随访43个月。胸腺瘤5年疾病特异性生存率100%、无复发生存率94%,胸腺癌分别为95%和79%,远期生存与复发率与开放或胸腔镜胸腺切除术相当。

要点

  • 机器人胸腺切除术治疗胸腺上皮肿瘤远期生存良好
  • 胸腺瘤5年疾病特异性生存率100%,胸腺癌95%
  • 胸腺瘤5年无复发生存率94%,胸腺癌79%

核心结论

  • 机器人胸腺切除术可获得良好的远期生存率和复发率,与开放或胸腔镜胸腺切除术相当。

研究设计与样本

  • 回顾性研究纳入158例接受机器人胸腺切除术的胸腺上皮肿瘤患者,随访超过1年,中位随访43个月(四分位距40个月),156例(98%)完成随访至研究结束。

主要发现

  • 患者平均年龄55.7±12.7岁,肿瘤平均大小4.6±2.1 cm,无术后死亡,术后并发症发生于7例(4.4%),术后中位住院时间2天(四分位距1-20天)。
  • 胸腺瘤132例(84%),胸腺癌24例(15%),神经内分泌肿瘤2例(1%);III期以上15例(IIIA期7例4%,IVA期5例3%,IVB期3例2%)。
  • 胸腺瘤5年疾病特异性生存率100%,胸腺癌95%;胸腺瘤5年无复发生存率94%,胸腺癌79%。

临床怎么用

  • 机器人胸腺切除术可作为胸腺上皮肿瘤的外科治疗选择,远期肿瘤学结局与开放或胸腔镜手术相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term outcomes of robotic thymectomy for thymic epithelial tumors (TETs) are not well known, even though the early postoperative outcomes have improved. This study aimed to report the long-term survival and recurrence in patients with TETs who underwent robotic thymectomies. METHODS: A total of 158 patients who underwent robotic thymectomy for TET and who were followed-up for more than 1 year were included in the study. The median follow-up time was 43 (interquartile range, 40) months, and 156 (98%) patients were followed completely until the end of the study period. RESULTS: The mean age of the patients was 55.7 ± 12.7 years, and the mean size of the tumor was 4.6 ± 2.1 cm. There was no postoperative mortality and postoperative complications occurred in 7 (4.4%) patients. The median length of the postoperative hospital stay was 2 (interquartile range, 1-20) days. Thymoma was the most common cell type (n = 132, 84%), and thymic carcinoma (n = 24, 15%) and neuroendocrine tumors (n = 2, 1%) were the next most common types. Advanced stages more than stage III were identified in 15 patients (stage IIIA: n = 7, 4%; stage IVA: n = 5, 3%; and stage IVB: n = 3, 2%). The 5-year disease-specific survival was 100% in thymoma and 95% in thymic carcinoma. The 5-year recurrence-free survival was 94% in thymoma and 79% in thymic carcinoma. CONCLUSIONS: Robotic thymectomy could achieve favorable long-term survival and recurrence rates, comparable to open or thoracoscopic thymectomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kang CH, Na KJ, Park S, et al. Long-Term Outcomes of Robotic Thymectomy in Patients With Thymic Epithelial Tumors. Ann Thorac Surg. 2020. PMID: 33129772. doi:10.1016/j.athoracsur.2020.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。